Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation (Q37976851)

26 August 2017

title

Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation (English)

1 reference

cost-effectiveness analysis

26 August 2017

main subject

1 reference

1 reference

1 reference

M Mahmoudi

1 reference

26 August 2017

C I Coleman

series ordinal

1 reference

26 August 2017

D M Sobieraj

series ordinal

1 reference

26 August 2017

publication date

1 February 2012

1 reference

International Journal of Clinical Practice

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

171-182

1 reference

Nicotine receptor partial agonists for smoking cessation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Regional, disease specific patterns of smoking-attributable mortality in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Smoking cessation: an overview of treatment options with a focus on varenicline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Interventions to reduce harm from continued tobacco use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Development of the health and economic consequences of smoking interactive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02877.X

10.1111/J.1742-1241.2011.02877.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference